Other News

CorMedix Inc. Announces New Commercial Agreement

Peripheral/Endo by Comments are Disabled

BERKELEY HEIGHTS, N.J., Sept. 19, 2024 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a new commercial supply contract with a top-tier mid-sized dialysis operator for the supply of DefenCath® (taurolidine and heparin) to dialysis clinics in the US. This new agreement will provide access to DefenCath for adult patients with kidney failure receiving hemodialysis through a central venous catheter at more than 250 outpatient dialysis clinics located across the United States.

Continue Reading →

CARMAT Launches a Capital Increase for an Initial Amount of €10.3 Million to Finance Its Activities Until at Least the End of 2024

Financial by 0 comments

This capital increase will be carried out through a public offering without preferential subscription rights and with a 7 trading days priority period, on an irreducible and reducible basis, for the benefit of CARMAT’s shareholders The initial amount of the capital increase may be increased up to €11.8 million in […]

Continue Reading →

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time

Coronary/Structural Heart by 0 comments

BOULDER, Colo.–(BUSINESS WIRE)–Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in […]

Continue Reading →

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

Financial by Comments are Disabled

SUNNYVALE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Company has regained full compliance with the Nasdaq Capital Market’s Listing Requirements as required by the Hearing Panel’s (the “Panel”) decision on May 13, 2024.

Continue Reading →

Edwards Launches SAPIEN 3 With Alterra Prestent in Europe for Transcatheter Pulmonic Valve Implantation

Coronary/Structural Heart by 0 comments

September 16, 2024 07:01 PM Eastern Daylight Time NYON, Switzerland–(BUSINESS WIRE)–Edwards Lifesciences today announced the launch in Europe of the SAPIEN 3 transcatheter pulmonary valve implantation (TPVI) system with Alterra adaptive prestent, expanding minimally invasive treatment options to a broader range of patients with congenital heart conditions. “I am proud […]

Continue Reading →

Novostia Announces New CEO and Secures Additional CHF 5.6 million in Funding

Financial by 0 comments

September 17, 2024 07:47 AM Eastern Daylight Time LAUSANNE, Switzerland–(BUSINESS WIRE)–Novostia, a pioneering medical technology company, specializing in the development of a disruptive heart valve prosthesis, at clinical stage, today announces a leadership transition alongside the successful completion of a CHF 5.6 million fund raise to further accelerate the company’s […]

Continue Reading →

Market Expansion for XARELTO in Peripheral Artery Disease Treatment through 2032: Forward-looking Insights and Sales Forecasts, Dynamics and Emerging Therapies – ResearchAndMarkets.com

Peripheral/Endo by 0 comments

DUBLIN–(BUSINESS WIRE)–The “XARELTO Market Size, Forecast, and Market Insight – 2032” report has been added to ResearchAndMarkets.com’s offering. “XARELTO Market Size, Forecast, and Market Insight – 2032” Post this The latest industry report provides a thorough analysis of the potential growth and impact of XARELTO for the treatment of Peripheral Artery Disease (PAD) in […]

Continue Reading →

ZONTIVITY Emerges as a Key Player in the Treatment of Peripheral Artery Disease with Promising Market Forecast Through 2032 – ResearchAndMarkets.com

Peripheral/Endo by 0 comments

September 17, 2024 12:09 PM Eastern Daylight Time DUBLIN–(BUSINESS WIRE)–The “ZONTIVITY Market Size, Forecast, and Market Insight – 2032” report has been added to ResearchAndMarkets.com’s offering. “ZONTIVITY Market Size, Forecast, and Market Insight – 2032” Post this ZONTIVITY, known for its efficacy in reducing thrombotic cardiovascular events, emerges as a significant pharmaceutical agent in […]

Continue Reading →
1 … 213 214 215 216 217 … 1,333